Chronic obstructive pulmonary disease, or COPD, is the 5th-leading cause of death in the United States and the cause of more ...

It was a perfect Saturday in March for getting some fresh air. But it also meant the return of a staple Milwaukee fundraiser.

Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.

Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...

Chronic obstructive pulmonary disease (COPD) is associated with an increase in stroke-related mortality in older individuals, according to study results presented at the International Stroke ...

As the UK National Screening Committee (UK NSC) reviews chronic obstructive pulmonary disease (COPD) screening, there is an opportunity to move ...

Over 141,000 people are receiving financial support through Personal Independence Payment for over 20 respiratory conditions.

Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special Administrative Regions (SARs) in Greater Chi ...

Great. Thank you for coming, everybody. I'm James Gordon, Barclays European pharma and biotech analyst. And today, I've got the pleasure of hosting a fireside with GSK. So we're going to hear from GSK ...

ResMed is a leader in CPAP machines and other medical devices that help millions breathe better.

BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart failure, yet no pharmacological therapy is approved for PAC suppression.